Lexaria Bioscience
LEXX
17 hedge funds and large institutions have $1.85M invested in Lexaria Bioscience in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
13% more funds holding
Funds holding: 15 → 17 (+2)
10% more capital invested
Capital invested by funds: $1.67M → $1.85M (+$173K)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.04% less ownership
Funds ownership: 11.46% → 11.41% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$5.98K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.76K |
| 3 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$470 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$85 |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$43 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$45.8K |
| 2 |
CC
Centiva Capital
New York
|
-$2.86K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.73K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.65K |
LEXX Hedge Fund Activity: Q1 2023 in Review
17 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q1 2023, worth a combined $1.85M — up 10% from $1.67M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LEXX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $5.98K. The largest seller was Citadel Advisors, exiting entirely with an estimated $45.8K sold.
- 17 institutional investors held Lexaria Bioscience (LEXX) as of Q1 2023, up from 15 in Q4 2022.
- Funds reported $1.85M of Lexaria Bioscience stock for Q1 2023, up 10% quarter-over-quarter.
- 3 funds opened new Lexaria Bioscience positions in Q1 2023 and 1 closed out, a net change of +2 holders.
- The largest Lexaria Bioscience buyer in Q1 2023 was Renaissance Technologies, an estimated $5.98K added.
- The largest Lexaria Bioscience seller in Q1 2023 was Citadel Advisors, an estimated $45.8K sold.
Based on aggregated 13F filings for Q1 2023.